MINOCA: The Heart Attack With Normal Arteries That Affects More Women Than Men

Her troponin was elevated. Her angiogram was clean. The catheterization report said: no obstructive coronary artery disease. The emergency department attending wrote “rule out ACS” in the discharge summary and sent her home.

Eight months later, her cardiologist at an academic medical center reviewed the case. The troponin pattern, the wall motion abnormality on the echo that had been obtained at 2 AM, the chest pain that brought her in: she had had a real heart attack. The diagnosis was MINOCA. Nobody had told her.

This is not a rare story. Reynolds and colleagues, writing in JAMA in 2011, estimated that up to 50% of women who present with MI findings and a clean angiogram are discharged without a working diagnosis. The phrase “rule out ACS” on the discharge summary is doing specific work: it closes the inquiry at the angiogram and removes the obligation to explain why the troponin rose. For the woman reading her discharge paperwork, it reads as clearance. She was not cleared. She had a heart attack that the system did not classify.

What MINOCA actually is

MINOCA stands for Myocardial Infarction with Non-Obstructive Coronary Arteries. The clinical definition requires three criteria: evidence of acute myocardial injury (rising and falling troponin pattern), evidence of ischemia (symptoms, ECG changes, or wall motion abnormality on imaging), and no culprit obstructive coronary stenosis above 50% on angiography. 5 / Solid

MINOCA accounts for approximately 6-15% of all MI presentations. It is not a single disease. It is a clinical presentation with multiple possible underlying causes. The angiogram shows clean arteries; the heart tells a different story.

61% of MINOCA patients are female. 5 / Solid This is not coincidence. The mechanisms that produce MINOCA map closely to the ways women’s coronary disease differs from the male model.

Why the angiogram misses it

Standard coronary angiography is designed to detect obstructive stenosis: cholesterol plaque narrowing the lumen to the point where blood flow is impaired. It sees blockages. It does not see:

Plaque erosion. In younger women, the predominant MI mechanism is not plaque rupture but plaque erosion: the fibrous plaque cap remains intact while the endothelial surface erodes, triggering a clot over an intact but denuded surface. The artery may appear near-normal on angiography because the plaque itself is not dramatically stenotic. The clot that formed has often dissolved by the time the catheterization is performed. 5 / Solid

This distinction was first systematically documented by Arbustini and colleagues in Heart in 1999, in a pathology study of 200 sudden coronary death cases. They found that plaque erosion was the dominant mechanism in women under 50, while plaque rupture predominated in older men. The implication was significant: a young woman’s MI often leaves behind an artery that appears structurally near-normal, because the disruption was surface-level rather than structural. Angiography, which reads lumen shape, will not reliably detect it. Intravascular imaging, specifically optical coherence tomography, can identify the denuded endothelial surface and the residual thrombus, but only if the clinician suspects erosion and orders the test.

Coronary vasospasm. Focal, reversible constriction of a coronary artery that resolves completely within minutes to hours. Standard angiography sees the resting anatomy. If the spasm has resolved before the catheter arrives, the artery looks normal. A real ischemic event occurred. The test could not capture it. Vasospasm is more common in women, particularly in association with microvascular dysfunction, and it is a mechanism that standard angiography is structurally incapable of capturing unless the spasm is occurring at the moment the dye is injected.

SCAD (Spontaneous Coronary Artery Dissection). The coronary artery wall tears, creating a false lumen that compresses the true lumen. SCAD accounts for approximately 35% of MIs in women under 50. On standard angiography, mild SCAD can be invisible or appear as a subtle haziness rather than a clear blockage. Optical coherence tomography (OCT) identifies SCAD that angiography misses.

Myocarditis. Viral or autoimmune inflammation of the myocardium mimicking MI. The troponin pattern and wall motion changes look like a heart attack. The arteries are not involved.

Takotsubo cardiomyopathy. Catecholamine-driven acute LV dysfunction, triggered by emotional or physical stress. 88.9% female. Presents with chest pain, ST elevation, wall motion abnormality, and elevated troponin. The angiogram is clean. The heart is temporarily stunned.

Coronary embolism. A clot originating elsewhere, most often from a cardiac source (atrial fibrillation, a left ventricular thrombus, a valvular lesion, or a patent foramen ovale with paradoxical embolism), lodges in the coronary artery and produces ischemia. The embolus may lyse before the catheterization, leaving a clean angiogram. This mechanism requires a separate hypercoagulable and structural workup that is not captured by angiography alone.

The prognosis is not reassuring

This is the information most often withheld from MINOCA patients.

One-year mortality in MINOCA: approximately 2-5%. Similar to obstructive MI. Five-year major adverse cardiovascular event rates are elevated compared to the general population without cardiac history. MINOCA is not a benign variant that resolves and leaves no footprint. 5 / Solid

The mechanisms matter here. Plaque erosion-related MINOCA carries recurrence risk. Vasospastic MINOCA carries risk of life-threatening arrhythmia if spasm is sustained. SCAD has a documented 14% recurrence rate at five years. Myocarditis carries risk of progression to dilated cardiomyopathy in a minority of cases.

A MINOCA patient who receives appropriate guideline-directed medical therapy (aspirin, statin, ACE inhibitor, beta-blocker) has meaningfully better outcomes than one who is discharged without treatment. 5 / Solid

The workup that MINOCA requires

Cardiac MRI is the critical missing test in most MINOCA cases. 5 / Solid

CMR can detect:

• Late gadolinium enhancement in the myocardium, distinguishing myocarditis (midwall pattern) from ischemic injury (subendocardial pattern)
• Regional wall motion abnormalities characterizing the extent and distribution of injury
• LV thrombus (anticoagulation target)
• Takotsubo morphology (apical ballooning, base spared)

Cardiac MRI identifies the MINOCA etiology in 70-80% of cases when performed within days to weeks of the event. Without it, the working diagnosis remains “unknown MINOCA,” and treatment is necessarily generic rather than targeted.

Vasospasm testing, specifically intracoronary acetylcholine or ergonovine provocation during cardiac catheterization, is the gold standard for diagnosing coronary vasospasm. It is underperformed in the United States but routine in Japan where vasospastic disease is most intensively studied. Women with MINOCA who had rest-predominant symptoms, nocturnal onset, or symptoms triggered by cold or emotional stress are reasonable candidates for provocative testing.

OCT (optical coherence tomography) can be performed during cardiac catheterization to identify SCAD that standard angiography misses, or to characterize plaque erosion morphology. If SCAD or erosion is suspected based on patient demographics and angiographic haziness, OCT adds diagnostic precision.

Hypercoagulable workup in patients with possible coronary embolism: antiphospholipid antibodies, protein C, protein S, factor V Leiden, prothrombin mutation. A bubble study or transesophageal echocardiogram to evaluate for patent foramen ovale and intracardiac sources of embolism is warranted when the clinical picture is consistent.

Echocardiography at the time of presentation and at follow-up characterizes left ventricular function, identifies Takotsubo morphology, and screens for valvular abnormalities that could be embolic sources.

What treatment looks like for each etiology

Treatment in MINOCA is not generic. It follows from the etiology, and the etiology is the reason the cardiac MRI and full workup matter before discharge or within days after.

Plaque erosion-related MINOCA is treated with dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor such as clopidogrel or ticagrelor) and high-intensity statin therapy. The statin addresses the underlying plaque biology; the antiplatelet therapy reduces the risk of recurrent thrombosis at the erosion site. ACE inhibitor and beta-blocker are added if left ventricular function is impaired. This regimen is directly parallel to what a patient with obstructive MI receives, which is why the “your arteries look fine” framing is so damaging: the patient who hears that phrase never asks about the medications she needed.

Vasospasm-related MINOCA requires calcium channel blockers, typically long-acting diltiazem or amlodipine. This is the one MINOCA subtype where beta-blockers are specifically contraindicated as first-line therapy. Beta-blockers can worsen vasospasm by allowing unopposed alpha-adrenergic vasoconstriction. A patient who is started empirically on a beta-blocker after MINOCA without a vasospasm workup may be on the wrong medication for her actual mechanism. Nitrates are added in refractory cases. Smoking cessation is mandatory: nicotine is a potent trigger for coronary spasm.

SCAD-related MINOCA is managed conservatively. Unlike atherosclerotic MI, SCAD does not benefit from aggressive anticoagulation or thrombolytics, which can extend the intramural hematoma and worsen the dissection. Unless there is a specific complication requiring intervention, the standard approach is beta-blocker for hemodynamic stability and blood pressure control, with conservative management and close follow-up. Aspirin is commonly used, though the evidence base specific to SCAD is still developing. Percutaneous coronary intervention in SCAD carries higher complication rates than in atherosclerotic disease and is generally avoided unless the vessel is critically compromised.

Myocarditis-related MINOCA is treated with ACE inhibitor and beta-blocker for left ventricular protection. Anti-inflammatory therapy depends on the specific pathology identified: giant cell myocarditis and eosinophilic myocarditis require immunosuppression, while viral myocarditis is managed supportively. Strenuous exercise is restricted for three to six months, which is one of the most impactful near-term recommendations and one that patients are rarely given because they were not told they had myocarditis in the first place.

Takotsubo cardiomyopathy typically resolves with supportive care. The left ventricular dysfunction is usually reversible over days to weeks. Beta-blockers are used for hemodynamic stability during the acute phase and may reduce catecholamine-driven myocardial stress. ACE inhibitor is added for patients with significant LV dysfunction. Most patients recover full LV function by six weeks. Recurrence risk is approximately 5-10% at five years, and patients with identified triggers (specific stressors, medications like epinephrine or dobutamine) should have those triggers documented and avoided.

The broader point: a MINOCA patient started on guideline-directed medical therapy before the etiology is known may be on the right drugs or the wrong drugs depending on which mechanism is eventually identified. The cardiac MRI and full workup are not bureaucratic steps. They are what makes treatment rational rather than reflexive.

Secondary Prevention After MINOCA: What the Evidence Shows for Long-Term Outcomes

The question of which medications a MINOCA patient should receive after discharge is less settled than the equivalent question after obstructive MI — but the available evidence points in a consistent direction: guideline-directed medical therapy improves long-term outcomes, particularly for patients whose etiology is plaque-related or inflammatory.

The largest dataset examining secondary prevention after MINOCA comes from the MINOCA-BAT study, reported by Lindahl and colleagues in JACC in 2017, which used Swedish national registry data covering 9,136 MINOCA patients discharged from hospital. At one year, patients on aspirin had a 35 percent lower risk of major adverse cardiovascular events compared to those not on aspirin. Patients on statins had an 18 percent lower risk of death or MI. ACE inhibitors or angiotensin receptor blockers were associated with a 22 percent risk reduction. Beta-blockers showed a 25 percent reduction in major events in the full MINOCA cohort. 4 / Promising These associations, adjusted for baseline characteristics, represent the strongest available real-world evidence that MINOCA patients benefit from the same secondary prevention portfolio as obstructive MI patients.

The nuance is in the mechanism. The MINOCA-BAT data cannot fully separate the benefit by underlying etiology, which means it is unclear whether beta-blockers are helpful or potentially harmful in the subset of patients whose MINOCA was caused by vasospasm. The concern is the same documented in obstructive disease: beta-blockade removes beta-2 mediated vasodilation and can worsen coronary spasm through unopposed alpha-adrenergic vasoconstriction. Until prospective data specifically in vasospasm-related MINOCA are available, this remains a clinical uncertainty, and identifying the mechanism through cardiac MRI and provocation testing is the prerequisite to an informed treatment decision.

For plaque erosion-related MINOCA, aspirin plus P2Y12 inhibition and high-intensity statin therapy follow the same logic as post-obstructive MI management, because the plaque biology is similar and the recurrence risk is real. For myocarditis-related MINOCA, ACE inhibitor therapy for left ventricular protection is indicated based on heart failure data even when the mechanism is inflammatory rather than ischemic. For Takotsubo, beta-blocker therapy during the acute phase and ACE inhibitor for ventricular recovery follow established protocols.

The common thread across mechanisms is that no MINOCA etiology provides a clinical rationale for discharging a patient with nothing. The woman discharged with “clean arteries” who receives no secondary prevention and no follow-up plan faces a one-year mortality rate similar to an obstructive MI patient and a multi-year recurrence risk that is not trivially low. The secondary prevention conversation belongs in the hospital, not in a follow-up appointment that may never be scheduled.

What to do this week

If you had a troponin-positive hospitalization with a clean angiogram and were discharged without a clear diagnosis, four steps:

1. Request your records. Get the discharge summary, the catheterization report, and the troponin values with timestamps. Confirm that a MINOCA workup was either performed or explicitly planned. If the discharge summary says “no obstructive CAD” and nothing else, the workup was not completed.

2. Ask about cardiac MRI specifically. Call the discharging cardiologist or your primary care provider and ask: “Has a cardiac MRI been ordered to identify the etiology of my elevated troponin?” If the answer is no, ask why and request a referral. Cardiac MRI is most informative within the first few weeks; do not wait.

3. Do not start or stop cardiac medications without talking to your cardiologist first. If you were discharged on a beta-blocker, do not stop it on your own, but do ask whether vasospasm was evaluated. The answer will tell you whether the drug choice was evidence-based or default.

4. Find a cardiologist experienced with MINOCA. Academic medical centers, women’s heart programs, and electrophysiology or heart failure programs with a specific interest in non-obstructive coronary disease are the right referral targets. Bring your records. Use the vocabulary in the next section.

The vocabulary to use at the next appointment

If you or someone you know had a troponin-positive hospitalization with a clean angiogram and was sent home without a diagnosis:

“I understand my angiogram showed no obstructive coronary disease. I would like to discuss whether I meet criteria for MINOCA and whether a cardiac MRI should be ordered to identify the etiology. I would also like to know whether I should be on guideline-directed medical therapy while this is being determined.”

The 2019 AHA Scientific Statement on MINOCA, authored by Tamis-Holland and colleagues and published in Circulation, establishes MINOCA as a confirmed clinical entity requiring systematic evaluation and treatment. Bring this citation to the appointment if needed.

Cross-links

For the full SCAD picture: SCAD: The Heart Attack That Tears the Artery Wall.

For the microvascular disease that shares MINOCA’s angiographic appearance: Your Angiogram Was Normal. You Are Not Fine..

For the Takotsubo mechanism in detail: Broken Heart Syndrome Is Not a Metaphor.

For how women’s cardiac symptoms get dismissed: Why Women’s Heart Disease Gets Dismissed.

Find out whether your cardiac risk picture has the features that make MINOCA more likely, and which signals to bring to your cardiologist.